Study Investigates Targeted Interventions to Improve Lung Cancer Screening Uptake in High-Risk Patients
HERTHENA-Lung02 Evaluates Patritumab Deruxtecan in EGFR-Mutated NSCLC
DART Trial Assesses Relationship Between ctDNA and Outcomes in Unresectable NSCLC
ASCO 2025: Dr. Alexi Archambault Discusses the First-Line Combination of Cemiplimab and Chemotherapy for NSCLC
ASCO 2025: Dr. Paul Conkling Shares Insights on PD-L1 Testing Practices in Metastatic NSCLC
The Oncology Forum: Expert Panel Weighs in On Advancements in the Lung Cancer Landscape